What is Haemonetics?
Haemonetics is a blood and plasma management technology company serving providers, patients, payers, hospitals, labs, and life-sciences operators.
- Category
- Blood and plasma management technology
- Headquarters
- Boston, MA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; NYSE: HAE
What is Haemonetics?
Haemonetics is a blood and plasma management technology company headquartered in Boston, MA.
Haemonetics operates in blood and plasma management technology and is included here as a public company account for sales research and directory coverage. Its official website and investor-facing materials position the business around Plasma collection, Blood management, Hemostasis management, with a buying center that usually spans finance, operations, IT, procurement, legal, and line-of-business leadership.
For sellers, Haemonetics is useful to profile because public-company signals make account planning more concrete. Current annual reports, investor presentations, earnings releases, job posts, product launches, facility expansion, and partner announcements are stronger signals than stale third-party summaries.
What does Haemonetics offer?
Haemonetics's profile centers on Plasma collection, Blood management, Hemostasis management, Hospital software.
- Plasma collection· Blood and plasma management technology
- Blood management· Blood and plasma management technology
- Hemostasis management· Blood and plasma management technology
- Hospital software· Blood and plasma management technology
- Cell salvage· Blood and plasma management technology
- Vascular closure· Blood and plasma management technology
How does Haemonetics make money?
Haemonetics makes money through commercial activity tied to blood and plasma management technology.
Haemonetics makes money through commercial activity tied to blood and plasma management technology. Depending on the operating unit, revenue may come from product sales, subscriptions, transaction fees, services, usage, occupancy, routing density, channel programs, or long-term customer contracts.
The practical growth levers are market expansion, pricing, utilization, operating efficiency, customer retention, product attach, supply-chain execution, and capital allocation. Relevant outreach should connect to measurable initiatives such as margin improvement, uptime, automation, compliance, customer experience, field productivity, or data quality.
Who leads Haemonetics?
Haemonetics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Haemonetics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Haemonetics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Haemonetics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Haemonetics's leadership?
Haemonetics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.haemonetics.com- Haemonetics investor relationsInvestor relations / corporate contactcontact via https://www.haemonetics.com
- Haemonetics media relationsMedia or communications contact routecontact via https://www.haemonetics.com
How is Haemonetics funded?
Haemonetics's current status is Public company; NYSE: HAE.
Haemonetics's current capital profile is best understood through its listed public-company status: Public company; NYSE: HAE. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor relations page and current exchange filings. Budget timing should be inferred from current initiatives, leadership priorities, geographic expansion, product launches, facility investments, and earnings-call commentary.
How did Haemonetics get here?
Haemonetics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingHaemonetics is foundedThe company begins building in blood and plasma management technology.
- Scale-upCommercial footprint expandsHaemonetics broadens its product, customer, or geographic reach.
- Public marketsPublic company; NYSE: HAEPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Haemonetics's competitors?
Haemonetics competes with larger incumbents and focused specialists in blood and plasma management technology.
- MedtronicGlobal medical technology incumbent.
- Boston ScientificLarge interventional medical-device competitor.
- AbbottHealthcare company spanning diagnostics, devices, nutrition, and diabetes care.
- StrykerOrthopedics, neurotechnology, and surgical-equipment company.
- Cardinal HealthHealthcare distribution and services provider.
Haemonetics — frequently asked questions
